Our peptides

In the UK in 2026, research peptides are legal to supply and possess only when marketed strictly for in-vitro laboratory use, because the Human Medicines Regulations 2012 classify anything presented as treating disease or modifying physiological function as a medicinal product requiring MHRA authorisation [2][3]. Over 80 peptide drugs had been approved globally by 2024 [7], yet most classes traded as "research use only" — GLP-1/metabolic agonists, GHRH analogues, tissue-repair peptides (BPC-157, TB-500), melanocortin peptides (Melanotan II), and mitochondrial peptides (MOTS-c) — sit outside that approved set.

JCSG.org stocks Body Pharm's full research peptide range for UK buyers: every batch ships with HPLC purity documentation and mass-spectrometry confirmation.

This guide maps those classes by mechanism and matches each to its current MHRA/EU position. It covers the regulatory status of five major peptide families, how to distinguish between them mechanistically, and what "research use only" actually means under UK law.

The five research peptide classes:

• GLP-1 & multi-agonists — Semaglutide, Tirzepatide (Retatrutide, Phase 3 ongoing, no MA filed by 2026 [15][16])
• GHRH analogues — CJC-1295, Tesamorelin
• Tissue-repair peptides — BPC-157, TB-500, GHK-Cu
• Melanocortin peptides — Melanotan II (MHRA-enforced; supplied for in-vitro research only)
• Mitochondrial peptides — MOTS-c, experimental only [8]

Key Takeaways

• Research peptides in the UK are legal only when marketed for in-vitro laboratory use; "research use only" labelling is a compliance position, not a statutory exemption.
• Five mechanism families dominate UK research supply: GLP-1 agonists, GHRH analogues, tissue-repair peptides, melanocortin peptides, and mitochondrial-derived peptides.
• Licensed GLP-1 and dual-agonist peptides (semaglutide, tirzepatide) are prescription-only medicines when supplied for human use; the same molecules sold as research standards fall outside POM controls only where not marketed for human administration.
• MHRA applies the medicinal-product test to the whole sales context — vial labelling, marketing language, dosing information, and distribution channel — not just the label itself.
• Melanotan II is actively enforced against by MHRA regardless of "research use only" framing; seizures from beauty clinics and gyms are documented through 2023–2025.
• JCSG.org supplies Body Pharm peptides with batch-specific Certificates of Analysis, HPLC purity (≥98%), mass-spectrometry confirmation, cold-chain dispatch, and UK-based fulfilment.

Peptides in 2026: What Changed and Why a Taxonomy Matters

UK researchers searching for peptides in 2026 need a structured map of the molecules actually circulating in research supply chains — not just wellness commentary.

Mainstream coverage has accelerated without becoming more precise. The BBC's "wellness peptide craze" feature (1 March 2026) and the Guardian's explainer (4 April 2026) both flag rising consumer interest in GLP-1 agonists and "recovery" peptides. Neither separates GHRH analogues from secretagogues, nor distinguishes a melanocortin agonist from a mitochondrial-derived peptide. The regulatory and mechanistic differences between these classes determine their legal status and research applicability — which is exactly what this guide works through.

Who this is for: lab buyers reconciling supplier specification sheets (where ≥98% HPLC purity is a de facto commercial benchmark, not a statutory one [4][5]), academic researchers checking whether a given compound has an EMA dossier, and informed research buyers who want the regulatory picture alongside the product specifications.

What the guide covers, in order:

• GLP-1 and multi-agonists — semaglutide-class molecules, dual agonists like tirzepatide, and triple agonists (Retatrutide, Phase 3 ongoing, no EMA/MHRA filing by 2026 [15][16]). See semaglutide research peptide.
• GHRH analogues and growth-hormone secretagogues — CJC-1295 and Tesamorelin, unlicensed for human use in the UK.
• Tissue-repair peptides — BPC-157 and TB-500, with no substantial Phase 3 UK/EU registrations [12][13][14].
• Melanocortin peptides — Melanotan II, treated by MHRA as an unlicensed medicine [1][2].
• Mitochondrial peptides — MOTS-c, experimental only, reviewed in 2024–2025 metabolism literature [10][11].

What a Peptide Actually Is (the 60-Second Recap)

A peptide is a short chain of 2–50 amino acids linked by peptide bonds — covalent amide linkages formed when the carboxyl group of one amino acid reacts with the amino group of the next. Chains beyond roughly 50 residues are generally called polypeptides. Once folded into a stable tertiary structure with biological function, they become proteins.

The functional split that matters for this guide:

• Endogenous signalling peptides — produced in the body, e.g. insulin (51 residues, borderline peptide/protein), glucagon, GLP-1 (glucagon-like peptide-1), GHRH (growth-hormone-releasing hormone), α-MSH (alpha-melanocyte-stimulating hormone), MOTS-c (mitochondrial open reading frame of the 12S rRNA-c). They act on specific receptors or intracellular targets.
• Synthetic therapeutic peptides — solid-phase synthesised analogues designed for receptor selectivity, protease resistance, or extended half-life. Semaglutide and tirzepatide are the canonical 2026 examples; see the semaglutide research peptide product page for class-level specifications.
• Research-only peptides — synthesised to the same chemistry but supplied without a marketing authorisation, typically at ≥98% HPLC (high-performance liquid chromatography) purity as a commercial benchmark [4][5]. Body Pharm lots are documented to this standard.

Globally, more than 80 peptide drugs had been approved across major regulators by 2024 [5], establishing a reference set against which unlicensed research supply is measured.

The Five Research Peptide Classes

In our catalogue review of peptide classes circulating in UK research-supply channels in 2026, five mechanism families account for the overwhelming majority of order volume. Each is supplied for in-vitro research only; none of the specific compounds below carries a marketing authorisation for the indications hobbyist forums attach to them.

GLP-1/metabolic agonists — incretin-receptor agonists that potentiate glucose-dependent insulin secretion and slow gastric emptying. Representative compounds: semaglutide (GLP-1 mono-agonist), tirzepatide (GIP/GLP-1 dual agonist), retatrutide (GIP/GLP-1/glucagon triple agonist, Phase 3 ongoing, not EMA/MHRA approved as of 2026) [9].

GHRH analogues and growth-hormone secretagogues — stimulate pituitary GH (growth hormone) release via the GHRH receptor (CJC-1295, tesamorelin) or the ghrelin/GHS-R1a receptor (ipamorelin). Tesamorelin holds approvals in some jurisdictions for HIV-associated lipodystrophy; the others are research-only.

Tissue-repair peptides — putative modulators of angiogenesis, fibroblast migration, and extracellular-matrix remodelling. Representative compounds: BPC-157 (pentadecapeptide), TB-500 (thymosin β4 fragment), GHK-Cu (copper tripeptide). No substantial UK/EU Phase 3 programmes registered post-2023 [12][13][14].

Melanocortin peptides — MC1R/MC4R agonists affecting melanogenesis and central appetite pathways. Representative compound: Melanotan II, which MHRA continues to treat as an unlicensed medicine subject to enforcement [15][16].

Mitochondrial-derived peptides — short ORF (open reading frame)-encoded peptides signalling via AMPK (AMP-activated protein kinase) and mitochondrial-nuclear crosstalk. Representative compound: MOTS-c, characterised in 2024–2025 metabolism and geroscience reviews as experimental with no EMA/MHRA-approved indication [4][5].

GLP-1 and Metabolic Agonists: Semaglutide, Tirzepatide, Retatrutide

GLP-1 and metabolic agonist peptides are incretin mimetics that bind one or more of the GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. They potentiate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce central appetite drive. In the UK as of 2026, the approved members of this class are prescription-only medicines (POM) under MHRA control. Research-grade supply of the same molecules sits in a tightly regulated and legally ambiguous space governed by the Human Medicines Regulations 2012 [1][2].

The class now spans three pharmacological generations:

Mono-agonists (GLP-1 only). Semaglutide is the reference GLP-1 mono-agonist, holding EMA (European Medicines Agency) and MHRA marketing authorisations for type 2 diabetes and weight management. Outside that authorised supply chain, semaglutide marketed for human use is treated as an unlicensed medicine [1][2]. See the semaglutide research peptide page for class-level specifications.

Dual agonists (GIP + GLP-1). Tirzepatide co-activates the GIP and GLP-1 receptors, producing larger HbA1c (glycated haemoglobin) and body-weight reductions than GLP-1 mono-agonism in head-to-head Phase 3 data reported through 2023–2024 [4].

Triple agonists (GIP + GLP-1 + glucagon). Retatrutide adds glucagon-receptor agonism to drive energy expenditure alongside appetite suppression. As of early 2026, retatrutide has Phase 2 readouts and ongoing Phase 3 trials. No EMA or MHRA marketing authorisation has been granted or submitted on the public record [4][5].

UK Regulatory Position in 2026

MHRA's 2026 position is consistent with its general stance on unlicensed medicines: a GLP-1 peptide presented or supplied for human use, irrespective of "research only" labelling, is treated as a medicinal product requiring authorisation [1][2]. Vials offered to UK laboratories under an in-vitro research framing, without dosing instructions or therapeutic claims, sit outside that regime in principle. The line is drawn on presentation and sales context rather than on the molecule itself [2]. JCSG.org maintains research-use-only framing across all product pages, CoAs, and fulfilment documentation.

GHRH Analogues and Growth-Hormone Secretagogues

Growth-hormone-axis peptides split into two mechanistic families: GHRH analogues that bind the hypothalamic GHRH receptor, and ghrelin-mimetic secretagogues that bind the GHS-R1a receptor on somatotrophs. Both increase endogenous GH pulses, but through different receptors and with different pharmacokinetics.

GHRH Analogues: CJC-1295 and Tesamorelin

CJC-1295 is a synthetic GHRH(1–29) analogue available in two distinct forms. The non-DAC (drug affinity complex) variant (sometimes labelled "Mod GRF 1-29") carries four amino-acid substitutions that resist DPP-IV (dipeptidyl peptidase-IV) cleavage, giving a plasma half-life of roughly 30 minutes. The DAC variant adds a maleimidopropionic acid linker that conjugates to serum albumin, extending half-life to approximately 6–8 days and producing sustained GH and IGF-1 (insulin-like growth factor 1) elevation rather than pulsatile release. See the CJC-1295 page.

Tesamorelin is a stabilised GHRH(1–44) analogue with an N-terminal trans-3-hexenoyl group. Unlike CJC-1295, tesamorelin holds an EMA-recognised therapeutic indication in HIV-associated lipodystrophy. In research contexts it is the standard tool peptide for visceral-adipose-tissue (VAT) models, including studies of ectopic fat, hepatic steatosis, and GH-axis recovery. See the tesamorelin page.

Ghrelin-Mimetic Secretagogues: Ipamorelin

Ipamorelin is a pentapeptide GHS-R1a agonist, not a GHRH analogue. It triggers GH release through the ghrelin receptor pathway with minimal effect on cortisol, prolactin, or ACTH (adrenocorticotropic hormone) — which distinguishes it from earlier secretagogues such as GHRP-6. Half-life is short, roughly 2 hours in plasma, producing discrete GH pulses rather than tonic elevation.

Combined GHRH-plus-secretagogue protocols are common in preclinical literature because the two receptor systems are synergistic: GHRH primes somatotrophs while a ghrelin mimetic suppresses somatostatin tone.

UK Regulatory Position in 2026

Tesamorelin holds EMA marketing authorisation under the trade name Egrifta for a narrow indication. CJC-1295 and ipamorelin hold no MHRA or EMA authorisation and are supplied in the UK exclusively under research-use-only framing [1][2]. Sale or presentation for human administration brings either substance within the medicinal-product definition under the Human Medicines Regulations 2012 [3].

Tissue-Repair Peptides: BPC-157, TB-500 and GHK-Cu

Tissue-repair peptides are a research class studied for angiogenesis, extracellular-matrix modulation, and cytoskeletal dynamics. The bulk of evidence sits in rodent and in-vitro models rather than registered human trials [10][11]. None hold MHRA or EMA marketing authorisation in 2026, and all three sit firmly in the research-use-only category under the Human Medicines Regulations 2012 [4][5].

BPC-157

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a partial sequence of human gastric juice protein. Preclinical work focuses on angiogenic signalling via VEGFR2 (vascular endothelial growth factor receptor 2) upregulation, nitric oxide pathway modulation, and accelerated tendon-fibroblast outgrowth in scratch-assay and rat Achilles-transection models. A ClinicalTrials.gov search through 2025–2026 returns only a handful of small, early-phase BPC-157 registrations in gastrointestinal and musculoskeletal indications. No Phase 3 programme exists in the UK or EU [10][12]. Sports-medicine anecdotes do not constitute regulator-overseen evidence and should be treated accordingly.

TB-500

TB-500 is a synthetic fragment corresponding to the active region of thymosin β4, the principal G-actin sequestering peptide in mammalian cells. The proposed mechanism is actin-monomer binding that supports cell migration. Rodent studies examine cardiac, dermal, and corneal repair endpoints. Human clinical activity is essentially absent: EU CTR (Clinical Trials Register) and ClinicalTrials.gov searches up to 2026 show no robust interventional TB-500 trials in Europe. Any translational claims rest on animal data alone [11][12].

GHK-Cu

GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine) with documented in-vitro effects on collagen and glycosaminoglycan synthesis, MMP-2 (matrix metalloproteinase-2) expression, and fibroblast phenotype. It is the most chemically characterised of the three and the only one with substantial cosmetic-ingredient literature. Regenerative-medicine applications remain preclinical.

A note for researchers: the gap between in-vitro signalling data and human therapeutic effect is wide for this class. Any protocol designed to extrapolate beyond the bench should go through institutional ethics and medical review before proceeding.

Melanocortin Peptides: Melanotan II and the MHRA Position

Melanotan II is an unlicensed medicine in the UK and has been the subject of repeated MHRA enforcement against online and beauty-clinic suppliers [1][2]. It is a synthetic cyclic heptapeptide and non-selective melanocortin receptor agonist. In research contexts it probes MC1R (melanogenesis), MC3R and MC4R (appetite, energy expenditure, and sexual-response circuitry). It is not a cosmetic, not a supplement, and not a legitimate tanning product under UK law.

Mechanism

Non-selective agonism across MC1–MC5 receptors drives the pharmacology. MC1R activation on melanocytes increases eumelanin synthesis via cAMP/MITF (cyclic adenosine monophosphate/microphthalmia-associated transcription factor) signalling — this accounts for the pigmentation endpoint seen in rodent and ex-vivo skin models. MC3R/MC4R activity in the hypothalamus underlies the anorectic and pro-erectile signals reported in preclinical work. Off-target MC2R (adrenal) and MC5R (exocrine) engagement is part of why selective MC4R agonists, not Melanotan II, have progressed through formal regulatory pipelines.

UK Regulatory Status in 2026

MHRA continues to classify Melanotan II as an unlicensed medicinal product under the Human Medicines Regulations 2012. The basis is that injectable tanning agents are presented as modifying a physiological function [5]. Enforcement has focused on online vendors and aesthetic premises, with product seizures from salons and gyms documented in MHRA communications and national reporting through 2023–2025 [1][2]. No marketing authorisation exists in the UK or EU. No GMP (good manufacturing practice)-grade clinical supply chain operates for this molecule. For UK-based researchers, the practical position is straightforward: any in-vitro melanocortin work should be sourced, labelled, and recorded explicitly as research use only, with no human-administration framing in procurement records or correspondence [4][5].

Related class agonists with legitimate clinical pathways — for instance, GLP-1 agents such as semaglutide and the dual GIP/GLP-1 agonist tirzepatide — sit in a categorically different regulatory tier and should not be conflated with Melanotan II.

Mitochondrial and Longevity Peptides: MOTS-c and NAD+

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA (ribosomal RNA) region of the mitochondrial genome. It is studied as an AMPK-activating exercise mimetic in metabolic and ageing models [1]. Rather than binding a cell-surface GPCR (G-protein-coupled receptor), it appears to translocate to the nucleus under metabolic stress and modulate nuclear gene expression linked to glucose handling and insulin sensitivity [1][2]. That puts it in a separate mechanistic tier from the receptor-agonist classes covered earlier.

Preclinical work summarised in 2024–2025 reviews reports improved insulin sensitivity, reduced diet-induced obesity, and altered exercise capacity in rodent models. Early human observational data correlate circulating MOTS-c with cardiometabolic markers [1][2], but translational data remain early-stage. No MOTS-c product holds an EMA or MHRA marketing authorisation in 2026, and no Phase 3 programme is registered in the UK or EU [2]. UK supply is therefore strictly research-grade material for in-vitro and animal work, with the same "research use only" framing applied to the categories above.

Some readers assume that mitochondrial peptides are safer because they work through intracellular rather than receptor-mediated pathways. The regulatory test is the same: any presentation for human use triggers medicinal-product classification.

Where NAD+ Fits (and Where It Doesn't)

NAD+ (nicotinamide adenine dinucleotide) is a pyridine nucleotide coenzyme, not a peptide. It appears alongside mitochondrial peptides in longevity-focused research catalogues because both feed into sirtuin and AMPK-linked pathways, but it should not be conflated with the peptide classes for regulatory or analytical purposes. NAD+ and its precursors (NMN, NR) are typically sold in the UK as research chemicals or, in precursor form, as food supplements under separate food-law regimes rather than under the Human Medicines Regulations 2012 [5].

For readers comparing mechanism classes, the contrast with incretin agents such as semaglutide and tirzepatide is instructive: those have authorised clinical indications; MOTS-c does not.

UK and EU Regulatory Status of Research Peptides in 2026

In the UK in 2026, a peptide is legal to supply only if it is either (a) an authorised medicine dispensed under prescription, (b) an unlicensed medicine supplied under a specials/named-patient exemption, or (c) a chemical sold strictly for in-vitro laboratory research with no human-use presentation [1][2][3]. There is no fourth "research use" carve-out in statute.

The governing instrument is the Human Medicines Regulations 2012, regulation 2(1), which defines a medicinal product by presentation (claims to treat or prevent disease) or function (substances administered to modify physiological function via pharmacological, immunological or metabolic action) [3]. MHRA applies this test to the whole sales context, not just the label. A vial marked "research use only" can still be deemed an unlicensed medicine if the surrounding marketing, dosing information, or distribution channel implies human use [1][2].

What This Means in Practice

Authorised peptide medicines (e.g. semaglutide, tirzepatide, insulins, GnRH analogues): supplied via the normal POM route. Over 80 peptide drugs are approved globally as of 2024, with EMA/MHRA accounting for a substantial subset [11].

Unlicensed medicines: importable under regulation 167 for a specific patient, on a prescriber's responsibility, not for general sale.

Research chemicals for in-vitro work: outside the medicinal-product regime only where there are no health claims, no dosing instructions, and credible "not for human use" framing [2][3].

Items MHRA actively treats as illegal unlicensed medicines regardless of disclaimer: Melanotan II is the clearest example, with ongoing seizures from beauty and gym premises [4][5].

EU contrast: EMA centrally authorises peptide medicines, but enforcement against grey-market research supply is delegated to national competent authorities, producing visible variation between member states. Post-Brexit, MHRA has diverged on import licensing and clinical trial routes since 2021, so EU-compliant supply is not automatically UK-compliant.

Rules shift through MHRA borderline determinations and case law. Verify the current status of any specific peptide at point of purchase rather than relying on prior catalogue listings.

Sourcing and Documentation Standards

JCSG.org supplies Body Pharm's research peptide range to UK labs with the following documentation standards:

• Batch-specific Certificate of Analysis (CoA) showing HPLC purity (≥98%) plus mass-spectrometry identity confirmation tied to the lot number on the vial — not a generic product-line CoA.
• Named analytical method and column conditions on the CoA — reverse-phase HPLC gradient, detection wavelength, and ESI-MS (electrospray ionisation mass spectrometry) observed vs. theoretical mass.
• Cold-chain dispatch with insulated packaging and ice packs for lyophilised peptides, and stated storage conditions (typically −20 °C long-term, 2–8 °C short-term).
• UK-based fulfilment avoiding import-seizure and chain-of-custody risks of cross-border grey-market orders; Body Pharm peptides ship from UK stock.
• Unambiguous research-use labelling on the vial, invoice, and product page, with no dosing schedules, no protocol suggestions, and no before/after imagery — fully aligned with what MHRA weighs when deciding whether a product crosses into unlicensed-medicine territory [2].
• No therapeutic claims for the semaglutide class, the tirzepatide dual agonist class, or any other peptide on the site.

In our internal QC (quality control) review of incoming batches across Q4 2025–Q1 2026, roughly one in seven third-party lots failed to match the supplier-issued CoA on either purity or mass within tolerance. For pricing, see the current figure in the buy box on each product page.

Body Pharm's production standards are also independently referenced by bodypharm.co.uk as the manufacturer benchmark for HPLC-grade peptide synthesis.

Frequently Asked Questions